Cargando…
The Extracellular Small Leucine-Rich Proteoglycan Biglycan Is a Key Player in Gastric Cancer Aggressiveness
SIMPLE SUMMARY: Approximately 80% of gastric cancer patients are diagnosed at advanced stages with an average five-year survival rate of less than 30%. Alterations of the extracellular matrix proteins have been largely demonstrated in all steps of the disease. Thus, studies for the identification of...
Autores principales: | Pinto, Filipe, Santos-Ferreira, Liliana, Pinto, Marta T., Gomes, Catarina, Reis, Celso A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001774/ https://www.ncbi.nlm.nih.gov/pubmed/33809543 http://dx.doi.org/10.3390/cancers13061330 |
Ejemplares similares
-
Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer
por: Niedworok, Christian, et al.
Publicado: (2013) -
The Small Leucine-Rich Repeat Proteoglycan Biglycan Binds to α-Dystroglycan and Is Upregulated in Dystrophic Muscle
por: Bowe, Mark A., et al.
Publicado: (2000) -
Roles of Two Small Leucine-Rich Proteoglycans Decorin and Biglycan in Pregnancy and Pregnancy-Associated Diseases
por: Halari, Chidambra D., et al.
Publicado: (2021) -
The Landscape of Small Leucine-Rich Proteoglycan Impact on Cancer Pathogenesis with a Focus on Biglycan and Lumican
por: Berdiaki, Aikaterini, et al.
Publicado: (2023) -
Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site
por: Monfort, Jordi, et al.
Publicado: (2006)